Ulixertinib in People With Histiocytic Neoplasms

计划入组 38 人 · 首次发布于 2024 年 5 月 13 日

Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease

计划入组 135 人 · 首次发布于 2021 年 8 月 31 日

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

计划入组 22 人 · 首次发布于 2020 年 11 月 23 日

second-generation anti-CALR CAR T-cell therapy (myeloproliferative neoplasms)

Luspatercept(Reblozyl)

Rx

Anagrelide(Xagrid, Agrylin, Anagrelide Viatris (previously Anagrelide Mylan))

C₁₀H₇Cl₂N₃O · Rx

Histiocyte Society

United States

NEOPLAS INNOVATION

United States

Landmark NHS Approval of Dabrafenib and Brentuximab-Vedotin Combination Offers New Hope for Patients with Rare Blood Cancers

Outcomes Remain Poor for Myeloproliferative Neoplasm Blast Phase Despite New Therapies

Azacitidine-Ruxolitinib Combination Shows Promise for Advanced Myeloproliferative Neoplasms